Invivyd, Inc.
Invivyd, Inc. (IVVD): 6 pipeline candidates · 1 upcoming catalyst · ~14 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
13.7 months
D/E 0.19 · 10% dilution
Lead: Approved
6 candidates
1 upcoming, next in ~44d
0 buys · 10 sells (180d)
A transparent, data-derived signal for Invivyd, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$255.9M
Cash
$184.2M
Quarterly Burn
$41.7M
Runway
13.7 mo
Revenue
$13.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| adintrevimab | Phase 2/Phase 3 |
| pemgarda | Approved |
| vby329 | Preclinical |
| vyd2311 | Phase 3 |
| vyd2311-md | Phase 3 |
| vyd2311-sd | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
137
Total value held
$342.6M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 66,188,660 | $85.7M |
| perceptive advisors llc | 41,718,606 | $54.2M |
| vanguard capital management llc | 20,148,652 | $26.2M |
| bvf inc/il | 19,525,000 | $25.4M |
| maverick capital ltd | 18,970,913 | $24.7M |
| eventide asset management, llc | 9,071,995 | $11.8M |
| driehaus capital management llc | 8,436,894 | $11.0M |
| state street corp | 6,935,648 | $9.0M |
| blackrock, inc. | 4,281,790 | $5.6M |
| siren, l.l.c. | 4,000,000 | $5.2M |
Showing top 10 of 137 institutional holders of Invivyd, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Invivyd, Inc.'s pipeline?
Invivyd, Inc. (IVVD) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Invivyd, Inc.'s lead drug candidate?
Invivyd, Inc.'s most advanced tracked candidate is adintrevimab (Phase 2/Phase 3) for Prevention and treatment of COVID-19.
What is Invivyd, Inc.'s next catalyst?
Invivyd, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Triple-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of" — expected August 1, 2026.
What is Invivyd, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Invivyd, Inc. has approximately 13.7 months of cash runway.
What is Invivyd, Inc.'s market capitalization?
Invivyd, Inc.'s market capitalization is approximately $255.9M.
Get the full picture on Invivyd, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.